New trends in glaucoma pharmacotherapy
Article Sidebar
Published:
Mar 31, 2019
Keywords:
galucoma, Rha kinase inhibitors, netarsudil, latanoprost bunod, neutroprotection, citicoline
Main Article Content
Abstract
Despite many methods of treating glaucoma, we still cannot affect all causes of this disease. Therefore, many substances with different mechanisms of action are investigated. Recently, 3 drugs have been introduced to the treatment: citicoline, netarsudil and latanoprost bunod, which will be discussed in this article.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Szumny D. New trends in glaucoma pharmacotherapy. Ophthatherapy [Internet]. 2019Mar.31 [cited 2024Nov.22];6(1):26-9. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/506
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Yang X, Zeng Q, Goktas E et al. T-Lymphocyte Subset Distribution and Activity in Patients with Glaucoma. Invest Ophthalmol Vis Sci. 2019; 60(4): 877-88.
2. Bucolo C, Platania CBM, Drago F et al. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol. 2018; 16(7): 978-92.
3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019. https://doi.org/10.1111/cxo.12853.
4. Khouri AS, Serle JB, Bacharach J et al. Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.03.002.
5. Kahook MY, Serle JB, Mach FS et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.01.003.
6. You Y, Joseph C, Wang C et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain. 2019; 142(2): 426-42.
7. Boyd ZS, Kriatchko A, Yang J et al. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci. 2003; 44(12): 5206-11.
8. Schmidl D, Schmetterer L, Garhöfer G et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31(2): 63-77.
9. McKinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002; 5(6): 780-7.
10. Tomita H., Nakazawa T, Sugano E et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002; 452(3): 263-8.
11. Tsai JC, Song BJ, Wu L et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007; 16(6): 567-71.
12. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002; 70(2): 133-9.
13. Parisi V, Oddone F, Ziccardi L et al. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Curr Neuropharmacol. 2018; 16(7): 919-32.
14. Parisi V, Oddone F, Roberti G. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther. 2019. https://doi.org/10.1007/s12325-019-0897-z.
15. Adams CM, Stacy R, Rangaswamy N et al. Glaucoma – Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018; 36(2): 25.
16. Dillinger AE, Guter M, Froemel F et al. Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy. Small. 2018; 14(50): e1803239.
2. Bucolo C, Platania CBM, Drago F et al. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol. 2018; 16(7): 978-92.
3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019. https://doi.org/10.1111/cxo.12853.
4. Khouri AS, Serle JB, Bacharach J et al. Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.03.002.
5. Kahook MY, Serle JB, Mach FS et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution. Am J Ophthalmol. 2019. https://doi.org/10.1016/j.ajo.2019.01.003.
6. You Y, Joseph C, Wang C et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain. 2019; 142(2): 426-42.
7. Boyd ZS, Kriatchko A, Yang J et al. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci. 2003; 44(12): 5206-11.
8. Schmidl D, Schmetterer L, Garhöfer G et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31(2): 63-77.
9. McKinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002; 5(6): 780-7.
10. Tomita H., Nakazawa T, Sugano E et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002; 452(3): 263-8.
11. Tsai JC, Song BJ, Wu L et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007; 16(6): 567-71.
12. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002; 70(2): 133-9.
13. Parisi V, Oddone F, Ziccardi L et al. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Curr Neuropharmacol. 2018; 16(7): 919-32.
14. Parisi V, Oddone F, Roberti G. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther. 2019. https://doi.org/10.1007/s12325-019-0897-z.
15. Adams CM, Stacy R, Rangaswamy N et al. Glaucoma – Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018; 36(2): 25.
16. Dillinger AE, Guter M, Froemel F et al. Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy. Small. 2018; 14(50): e1803239.